健友股份 (603707)

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

ASH

Tags

SSE 380 IndexSpecial Purpose LoansWeight Loss DrugsInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareContains Convertible BondsBuyback PlansGuozheng Growth IndexSmall Cap GrowthOverseas BusinessBiological ProductsMargin Trading and Securities Lending医药生物Chemical Pharmaceuticals

K-Line Chart

No K-line data available

Company NameNanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
Listing Date2017-07-19
Issue Price7.21RMB
Registered Capital161563.496910k RMB
Legal RepresentativeTang Yongqun
Registered AddressPlot MA010-1, Nanjing High-tech Development Zone, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessCovers the entire industry chain of R&D, production, and marketing in the pharmaceutical field, and is a nationally recognized high-tech enterprise. Main products cover cardiovascular, anti-tumor, anti-infective, and surgical adjuvant drug fields. The company's products primarily consist of the full range of heparin products, including high-quality heparin active pharmaceutical ingredients (APIs), low molecular weight heparin preparations, and other major varieties, coordinated with the R&D, production, and sales of anti-tumor drugs and other pharmaceutical categories.
Company ProfileNanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "Nanjing Jianyou Pharmaceutical Company" or "the Company") is located in the Nanjing High-tech Industrial Development Zone, with a registered capital of 423.5 million RMB. The enterprise type is a joint-stock limited company (joint venture between Taiwan, Hong Kong, Macao, and mainland China). Nanjing Jianyou Company was established in 2000, formerly known as Nanjing Second Biochemical Pharmaceutical Factory. It is one of China's early pharmaceutical enterprises engaged in heparin extraction, purification, and the development of structural confirmation methods for heparin-like mucopolysaccharide products, with over 20 years of experience in heparin product production. In 2008, the company was recognized as a National High-tech Enterprise. In 2012, it was designated as the Jiangsu Provincial Engineering Technology Research Center for Mucopolysaccharide Biochemical Drugs. In 2013, it received the title of Jiangsu Provincial Enterprise Technology Center. In 2014, it was recognized as a Provincial-level Engineering Center by the Provincial Development and Reform Commission. The company has long served as the Chairman Unit of the Heparin Sodium Branch of the China Chamber of Commerce for Import & Export of Medicines & Health Products. The company invested 500 million RMB in the Nanjing High-tech Zone to build a high-speed production line with leading capacity in Asia, construct one of the few high-end production lines in Asia equipped with isolators, achieve modular scalability of the plant, and build China's first sterile preparation production line to pass FDA production quality standards, representing the high-end level of China's industry. It also broke the bottleneck for Chinese pharmaceutical factories selling sterile preparations in the US market.

Stock Details

1. Key Indicators

  • Total Shares(W): 161563.50
  • Circulating A-Shares(W): 161563.50
  • Earnings Per Share(RMB): 0.2700
  • Net Assets Per Share(RMB): 4.1503
  • Operating Revenue(W RMB): 292574.39
  • Total Profit(W RMB): 46208.90
  • **Net Profit Attributable to Parent(W RMB) **: 42946.72
  • Net Profit Growth Rate(%): -29.11
  • Weighted Return on Equity(%): 6.4700
  • Operating Cash Flow Per Share(RMB): 0.5570
  • Undistributed Profit Per Share(RMB): 2.4364
  • Capital Reserve Per Share(RMB): 0.3635

2. Main Business

The main business covers:

  • Research, development, production, and sales of pharmaceutical raw materials and preparations.

3. Company Basic Information

  • Company Name: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
  • Listing Date: 2017-07-19
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 16 Xuefu Road, Nanjing High-Tech Industrial Development Zone, Jiangsu Province
  • Website: https://www.nkf-pharma.com
  • Company Profile: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. was established through the overall transformation of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. On February 27, 2011, Tang Yongqun, Xie Juhua, Huang Xiwei, and Coastal Group jointly signed the "Sponsor Agreement for the Overall Change of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. to Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.", deciding to transform King-Friend Limited into King-Friend Co., Ltd. According to the "Audit Report" issued by Tianheng Firm (Tianheng Audit No. (2011) 100), King-Friend Limited converted its net assets of 340,366,147.37 yuan as of January 31, 2011 into 120,000,000 shares, with a par value of 1 yuan per share, and the remaining 220,366,147.37 yuan was included in the capital reserve. On March 1, 2011, Tianheng Firm issued the "Capital Verification Report" (Tianheng Verification [2011] No. 015) for the company's establishment through overall change. On March 3, 2011, the company held its founding meeting. On March 8, 2011, the Nanjing Administration for Industry and Commerce issued the "Business License" (Registration No. 320191000010753) to King-Friend Co., Ltd.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Jiangsu Coastal Development Group Co., Ltd. General Legal Person 34416.50 21.30
2 E Fund Management Co., Ltd. - China Life Insurance Company Limited - Participating Policy - E Fund China Life Shares Growth Equity Portfolio Single Asset Management Plan (Available for Sale) Asset Management Plan 1819.34 1.13
3 Basic Pension Fund 1205 Portfolio National Team 1560.95 0.97
4 E Fund Management Co., Ltd. - Social Security Fund 17042 Portfolio National Team 1297.29 0.80
5 E Fund Quality Momentum Three-Year Holding Mixed Securities Investment Fund Class A Public Fund 1248.65 0.77
6 Hong Kong Securities Clearing Company Limited Northbound Capital 948.61 0.59
7 E Fund Kexiang Mixed Securities Investment Fund Public Fund 792.80 0.49
8 Everbright Prudential Credit Tianyi Bond型 Securities Investment Fund Class A Public Fund 556.06 0.34
9 Zheshang Zhixuan Pioneer One-Year Holding Mixed Securities Investment Fund Class A Public Fund 72.04 0.04
10 Hengyue Medical Health Selected Mixed Securities Investment Fund Class A Public Fund 22.54 0.01

5. Concept Sectors

  • Convertible Bonds
  • Innovative Drugs
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • Share Buyback Plan
  • Overseas Business
  • Special Loans
  • SSE 380
  • Small-Cap Growth
  • SZSE Growth

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information